纽祺(上海)健康科技有限公司

预测:干细胞行业2021年达到1600亿美元  间充质干细胞应
用成为主流

2017全国两会已召开,基于人工智能、虚拟现实、大数据、生物医药等产业领域的颠覆性前沿技术正受到越来越多的关注,干细胞与再生医学技术作为生物医药领域具有爆发力的分支,正在被广泛视为有效应对癌症、糖尿病等重大疾病挑战的重要手段。
Summary
Polyplus-transfection® SA, the leading biotechnology company that supports the gene and cell therapy market by supplying innovative transfection solutions, today announces it will make available to the market a novel transfection reagent FectoVIR®-AAV in May 2020. The reagent has been specifically developed to improve AAV (adeno-associated virus) production in suspension cell culture system for large-scale manufacturing.
Summary
Polyplus-transfection® SA, the leading biotechnology company that supports the gene and cell therapy market by supplying innovative transfection solutions, today announces it will make available to the market a novel transfection reagent FectoVIR®-AAV in May 2020. The reagent has been specifically developed to improve AAV (adeno-associated virus) production in suspension cell culture system for large-scale manufacturing.

Summary
Polyplus-transfection® SA, the leading biotechnology company that supports gene and cell therapy by supplying innovative transfection solutions, today announces the availability of the first GMP-grade transfection reagent PEIpro®-GMP in additional conditioning that will ensure additional flexibility and cost-efficiency.

首页            关于我们            产品中心            新闻中心            加入我们
xxx@.co.m
020-000000
上海市